Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

PHASE4RecruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

October 7, 2021

Primary Completion Date

April 1, 2027

Study Completion Date

March 31, 2028

Conditions
Influenza, Human
Interventions
BIOLOGICAL

Seasonal influenza vaccine

The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Stanford University

OTHER

collaborator

The Scripps Research Institute

OTHER

lead

University of Pennsylvania

OTHER